Allworth Financial
RNAC icon

Allworth Financial’s Cartesian Therapeutics RNAC Stock Holding History

Allworth Financial’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$8.07K Hold
774
– – ﹤0.01% 3973
2026
Q2 		$8.07K Buy
774
+648
+514% +$4.8K ﹤0.01% 3851
2026
Q1 		$775 Buy
+126
New +$898 ﹤0.01% 4639
2025
Q3 		– Sell
-15
Closed -$156 – 5024
2025
Q2 		$156 Buy
+15
New +$160 ﹤0.01% 4348

Other funds holding RNAC

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Privium Fund Management
Privium Fund Management Amsterdam, Netherlands $516M AUM 18.66% 1-Year Est. Return
Fedenia Advisers
Fedenia Advisers Madison, Wisconsin $425M AUM 89.76% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Miller Financial Services
Miller Financial Services Marshall, Michigan $132M AUM 10.64% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Wedbush Securities
Wedbush Securities Los Angeles, California $3.95B AUM 25.45% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
North Star Investment Management
North Star Investment Management Chicago, Illinois $1.85B AUM 21.53% 1-Year Est. Return

Allworth Financial's RNAC Position: Q3 2026 in Review

Allworth Financial held its Cartesian Therapeutics (RNAC) position steady in Q3 2026 at 774 shares worth $8.07K. The position accounts for ﹤0.01% of the portfolio, ranked #3973.

Allworth Financial first reported a position in RNAC in Q2 2025 and has held it in 4 quarters since. 30 funds tracked by Wall St. Rank hold RNAC as of Q3 2026.

  • Allworth Financial held 774 shares of Cartesian Therapeutics worth $8.07K as of Q3 2026.
  • Allworth Financial left its Cartesian Therapeutics share count unchanged in Q3 2026.
  • Cartesian Therapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q3 2026, its #3973 holding.
  • Allworth Financial first reported a position in Cartesian Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 30 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q3 2026.

Based on Allworth Financial's 13F filing for Q3 2026, filed 6 Nov 2026.